GlobeNewswire Inc | Sep 23, 2021 05:47PM EDT

September 23, 2021

ATLANTA, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that Kathy Lee-Sepsick, chairman, president and chief executive officer, will participate in a presentation at The MedTech Conference. Ms. Lee-Sepsick will speak on a panel in a session, entitled, Early-Stage Medtech and Going Public. The MedTech Conference, an annual event powered by AdvaMed, convenes the worlds leaders in medical technology and will be held on a hybrid basis from September 21st-30th this year.

Below is the session information for Early-Stage Medtech and Going Public:

Date and Time: Thursday, September 30 at 10:00 a.m. 10:35 a.m. ET

Location: Hyatt RegencyMinneapolis, Great Lakes Ballroom, 1300 Nicollet Mall, Minneapolis, MN 55403

About FemasysFemasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health. Its two lead product candidates are FemBlocpermanent birth control and FemaSeedlocalized directional insemination for infertility. The Companys product for fallopian tube assessment by ultrasound, FemVue, is currently marketed in the United States. Femasys is also advancing FemCerv, a technology platform for tissuesampling intended to be marketed alongside its other women-specific medical products in the physicians officesetting.

Contacts:

Investors

Chuck PadalaLifeSci Advisors, LLC+1-917-741-7792chuck@lifesciadvisors.com

MediaSky StriarLifeSci Communicationssstriar@lifescicomms.com

Femasys Inc.

Investor Contact:IR@femasys.com

Media Contact:Media@femasys.com